An observational study in Hypophosphatasia, sponsored by University of Bonn. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-07.
Sponsored by University of Bonn · Observational
With hypophosphatasia still being frequently overlooked and misdiagnosed, the primary aim of this prospective observational study is to determine the prevalence of hypophosphatasia in adult patients in rheumatology, and beyond that to establish an algorithm that promotes early hypophosphatasia detection in clinical practice.
Hypophosphatasia (HPP) is a rare genetic disorder (1-3/300,000 severe cases in Europe) caused by one or more mutations in the alkaline phosphatase (ALP) gene. Hypomineralization results in symptoms such as arthralgias, insufficiency fractures, and poor dental status beginning in childhood. A fatal outcome is conceivable in circumstances of early infancy first presentation. In consistency with the musculoskeletal complaint pattern, HPP is far more common in the rheumatology patient population than in the general population.
However, HPP is still frequently misdiagnosed as some other form of bone disease (e.g., rickets, osteomalacia, or osteoporosis). Therefore, implementation of a clinically applicable algorithm for early hypophosphatasia detection is needed.
The primary aim of this prospective observational study is to determine the prevalence of hypophosphatasia in adult patients in rheumatology. Moreover, a further goal is to establish an algorithm that reliably separates adult HPP patients from other, rheumatologic and bone diseases.
45 studies on the registry are indexed under Hypophosphatasia; 10 are open to participants now.
This study's planned enrollment of 60 is close to the median of 58 across 22 observational studies indexed under Hypophosphatasia.
Browse Hypophosphatasia studies →University of Bonn is the lead sponsor of 36 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any adult patient presenting at the University Hospital Bonn's rheumatology department with musculoskeletal complaints within the timeframe of the study conduct.
Exclusion Criteria:
Patients with persistant hypophosphatasemia are highly suspicious for hypophosphatasia, and as such are the main focus of this study. In case of persistently low alkaline phosphatase (2nd measurement, 2-4 weeks after the 1st measurement) with normal serum calcium and phosphate values (exclusion of secondary hypophosphatemia due to e.g. rickets or malnutrition) and exclusion of other causes of secondary hypophosphatemia, genetic testing for a pathological ALP gene is performed as part of routine diagnostics. This study involves the structured recording of specific symptoms, the entire course of the disease since childhood, laboratory parameters and genetic testing.
Diagnostic Test: Second alkaline phosphatase measurement · Diagnostic Test: Extended laboratory diagnostics · Diagnostic Test: Symptom and clinical findings checklist for hypophosphatasia · Diagnostic Test: SF-36 · Diagnostic Test: Short physical performance battery (SPPB) score · Diagnostic Test: Physical examination · Diagnostic Test: Recording of vital signs · Diagnostic Test: Bioelectrical Impedance Analysis · Diagnostic Test: Genetic testing of the alkaline phosphatase gene
In patients, in which the initial hypophosphatasemia does not confirm with the second ALP testing, the former suspicion of hypophosphatasia must be discarded. With the exclusion of a hypophosphatasia (characterized by a persistant hypophosphatasemia among other criteria) this group of patients qualifies as a control group of patients without hypophosphatasia. Data from this control group will be analyzed in order to investigate patient historical, clinical and laboratory features that may help in the discrimination of hypophosphatasia patients against healthy individuals.
Diagnostic Test: Second alkaline phosphatase measurement · Diagnostic Test: Symptom and clinical findings checklist for hypophosphatasia · Diagnostic Test: SF-36 · Diagnostic Test: Short physical performance battery (SPPB) score · Diagnostic Test: Physical examination · Diagnostic Test: Recording of vital signs · Diagnostic Test: Bioelectrical Impedance Analysis
(2-4 weeks after the 1st measurement)
Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
Quality of life questionnaire
The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
A full rheumatological examination will be performed.
(including body temperature, blood pressure, heart rate)
A body composition measurement by BIA (Bioelectrical Impedance Analysis \[proportional mass of muscle, water and fat in kg\]) will be performed.
Investigation of mutations regarding the alkaline phosphatase gene
Prevalence of hypophosphatasia in adult patients in rheumatology
The primary aim of this prospective observational study is to determine the prevalence of hypophosphatasia in adult patients presenting with musculoskeletal symptoms in rheumatology.
Time frame: 24 months
Frequency of musculoskeletal pathology in hypophosphatasia patients in comparison with normal controls.
Frequency of musculoskeletal pathology in people with biochemistry suggestive of hypophosphatasia and positive ALP gene test as compared with normal controls.
Time frame: 24 months
Health-related quality of life: Short Form-36
The possible score ranges from 0 to 100 points, where 0 points represent the greatest possible health limitation, while 100 points represent no health limitation at all.
Time frame: 24 months
Frequency of specific symptoms and clinical findings in patients with hypophosphatasia
This will be derived from the symptom and clinical findings checklist.
Time frame: 24 months
Frequency of specific patient history findings and the occurence of hypophosphatasia
Data will be derived from the medical history of hypophosphatasia patients (patient clinical data will be collected regarding the diagnosis, onset, progression, treatment course and outcome for patients with hypophosphatasia)
Time frame: 24 months
Correlation between physical performance abnormalities and hypophosphatasia
Physical performance is determined by standardized "short physical performance battery"
Time frame: 24 months
Correlation between body composition abnormalities and hypophosphatasia
Body composition is determined by bioelectrical impedance analysis.
Time frame: 24 months
Plan to share: Yes — Data will be available upon reasonable request
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bonn